NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Enjoji, Munechika ^a,b   MacHida, Kazuyuki ^a   Kohjima, Motoyuki ^b   Kato, Masaki ^c   Kotoh, Kazuhiro ^c   Matsunaga, Kazuhisa ^a   Nakashima, Manabu ^a   Nakamuta, Makoto ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID; ADIPOCYTOKINE; AZETIDINE DERIVATIVE; CARBOHYDRATE; HYPOCHOLESTEROLEMIC AGENT; MEMBRANE PROTEIN; NPC1L1 PROTEIN, HUMAN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOGRAPHY; FATTY LIVER; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; NONALCOHOLIC FATTY LIVER; CHEMISTRY; DRUG ANTAGONISM; INJURY; LIVER; METABOLISM; MIDDLE AGED; OBESITY;

ADIPOKINES; ADULT; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARBOHYDRATES; CHOLESTEROL; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OBESITY; URSODEOXYCHOLIC ACID;

EID: 77955519012     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-29     Document Type: Article

References (21)

1. Nonalcoholic fatty liver disease. Angulo P, N Engl J Med 2002 346 1221 1231 10.1056/NEJMra011775 11961152 (Pubitemid 34984585)
2. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ, Gastroenterology 1999 116 1413 1419 10.1016/S0016-5085(99)70506-8 10348825 (Pubitemid 29258890)
3. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S, J Gastroenterol 2003 38 954 961 10.1007/s00535-003-1178-8 14614602 (Pubitemid 37455782)
4. Clinical and pathological features of non-alcoholic steatohepatitis. Nonomura A, Enomoto Y, Takeda M, Tamura T, Kasai T, Yoshikawa T, Nakamine H, Kojima H, Uemura M, Zen Y, Minato H, Hepatol Res 2005 33 116 121 10.1016/j.hepres.2005.09.017 16275057 (Pubitemid 41799787)
5. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, Fujino T, Aoyagi Y, Fukuizumi K, Yoshimoto T, Takemoto R, Miyahara T, Harada N, Hayata F, Nakashima M, Enjoji M, Scand J Gastroenterol 2009 44 471 477 10.1080/00365520802588133 19058085
6. Dietary links to NAFLD in non-obese patients. Allison SJ, Nat Rev Gastroenterol Hepatol 2009 6 320 10.1038/nrgastro.2009.75
7. Central role for liver × receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Chen G, Liang G, Ou J, Goldstein JL, Brown MS, Proc Natl Acad Sci USA 2004 101 11245 11250 10.1073/pnas.0404297101 15266058 (Pubitemid 39038332)
8. Autoregulation of the human liver × receptor promoter. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P, Mol Cell Biol 2001 21 7558 7568 10.1128/MCB.21.22.7558-7568.2001 11604492 (Pubitemid 32988767)
9. Cross-talk between fatty acid and cholesterol metabolism mediated by liver × receptor Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA, Nebb HI, Mol Endocrinol 2000 14 741 752 10.1210/me.14.5.741 10809236 (Pubitemid 32266072)
10. Liver × receptor as insulin-mediating factors in fatty acid and cholesterol biosynthesis. Tobin KA, Ulven SM, Schuster GU, Steineger HH, Andresen SM, Gustafsson JA, Nebb HI, J Biol Chem 2002 277 10691 10697 10.1074/jbc.M109771200 11781314 (Pubitemid 34975649)
11. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Nakamuta M, Kohjima M, Morizono S, Kotoh K, Yoshimoto T, Miyagi I, Enjoji M, Int J Mol Med 2005 16 631 635 16142397
12. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M, Int J Mol Med 2007 20 351 358 17671740
13. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Kohjima M, Higuchi N, Katoh M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Enjoji M, Takayanagi R, Nakamuta M, Int J Mol Med 2008 21 507 511 18360697 (Pubitemid 351802646)
14. Liver × receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Higuchi N, Kato M, Syundo N, Tajiri H, Tanaka M, Yamashita N, Kohjima M, Kotoh K, Nakamuta M, Takayanagi R, Enjoji M, Hepatol Res 2008 38 1122 1129 10.1111/j.1872-034X.2008. 00382.x 18684130
15. Impact of cholesterol metabolism and the LXR-SREBP-1c pathway on nonalcoholic fatty liver disease. Nakamuta M, Fujino T, Yada R, Yada M, Yasutake K, Yoshimoto T, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Enjoji M, Int J Mol Med 2009 23 603 608 19360318
16. Reduced hepatic expression of adipose tissue triglyceride lipase and CGI-58 may contribute to the development of non-alcoholic fatty liver disease in patients with insulin resistance. Kato M, Higuchi N, Enjoji M, Scand J Gastroenterol 2008 43 1018 1019 10.1080/00365520802008140 19086170
17. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Enjoji M, Yada R, Fujino T, Yoshimoto T, Yada M, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Nakamuta M, Hepatol Int 2009 3 490 496 10.1007/s12072-009-9137-y
18. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipids secretion via the PPAR-MDR3 pathway. Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nishinakagawa T, Machida K, Matsunaga K, Nakashima M, Kotoh K, Enjoji M, Int J Clin Pharmacol Ther 2010 48 22 28 20040336
19. Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review. Kidambi S, Patel SB, Xenobiotica 2008 38 1119 1139 10.1080/00498250802007930 18668442
20. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA, J Biol Chem 2005 280 12710 12720 10.1074/jbc.M409110200 15671032
21. Ezetimibe improves liver steatosis and insulin resistance in an obese rat model of the metabolic syndrome. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M, FEBS Lett 2007 581 5664 5670 10.1016/j.febslet.2007.11.023 18022391 (Pubitemid 350179776)